Greene Barry E 4

What Happened
Barry E. Greene, a director of Dyne Therapeutics (DYN), was granted a derivative award covering 57,463 shares on June 22, 2026. The Form 4 reports the acquisition price as $0.00 and a total reported value of $0 — this is an equity award (option/derivative), not an open-market purchase or sale.

Key Details

• Transaction date: June 22, 2026; Form 4 filed June 23, 2026 (timely filing).
• Transaction type/code: Grant/Award of derivative security (A).
• Amount: 57,463 underlying shares reported; price shown as $0.00; reported value $0.
• Vesting: Footnote F1 — the option was granted 6/22/2026 and vests over three years in equal monthly installments through 6/22/2029.
• Shares owned after transaction: Not specified in the provided filing.
• No sale or exercise reported — this is a compensation award, not a cash transaction.

Context
This was an equity award to a director that will vest over time. Such grants are commonly part of director compensation and do not by themselves signal buying or selling conviction. For retail investors, purchases are generally a clearer bullish signal; awards primarily reflect company compensation practices.